Pfizer Downgrades 2024 Forecast Due to Flagging Vaccine Sales, Sinking Stock Price

Pfizer chopped its 2024 outlook, after already lowering its 2023 forecast earlier this year.

Pfizer CEO Albert Bourla at the New York Stock Exchange in New York, on Jan. 17, 2019. Drew Angerer/Getty Images

Pfizer executives on Dec. 13 said they expect to make less money than expected in 2024, a few months after acknowledging 2023 sales would likely be lower than expected due to flagging COVID-19 vaccine and drug uptake.

Pfizer shares hit a 10-year low after the announcement.